Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments
Share
Follow Us
Boehringer hails hepatitis C candidate
Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients’ treatment time and help in hard-to-treat cases.
The treatment of hepatitis C has moved forward recently, with Janssen’s Incivo (telaprevir) and Merck and Roche’s Victrelis (boceprevir) both recently launched in Europe.
Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo.
The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) – which is only successful in about half of all cases – in previously untreated genotype 1 (GT1) HCV patients.
Continue reading this entire article:
http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate
